Author

F. Yılmaz

h-index 3 View on Semantic Scholar

We have 3 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Design, Synthesis, and Anticancer Evaluation of Novel Chalcone Derivatives Bearing Piperazine and Morpholine Moieties.

Cancer remains one of the leading causes of mortality worldwide, highlighting the need for novel anticancer agents with improved efficacy and selectivity. In this study, a series of chalcone derivatives bearing phenylpiperazine, 2-fluorophenylpiperazine, and morpholine moieties (1a-g, 2a-g, and 3a-g) were designed, syn...

N. Çalışkan, F. Yılmaz, O. E. Eyupoğlu et al. · Archiv der Pharmazie · 0 citations

Sep 2026

Novel Benzimidazole–Isatin Hybrids as Potential Therapeutics for Alzheimer’s Disease: Design, Microwave-Assisted Synthesis, and Structure–Activity Relationship

This study underscores microwave irradiation as a highly efficient and superior synthetic approach, establishing benzimidazole–isatin hybrids—most notably compound Vi—as promising pharmacophoric scaffolds for drug development targeting Alzheimer’s disease.

F. Yılmaz, G. Akyüz · Russian journal of bioorgani... · 1 citation

Aug 2026

Glycine-conjugated coumarin-quinazoline hybrids as potent anticancer agents: synthesis, cytotoxicity, SAR and molecular docking studies.

G glycine conjugation of a coumarin-quinazoline hybrid has not been reported previously, and the results identify it as a substituent- and cell-line-dependent strategy for improving anticancer potency and selectivity.

N. Çalışkan, M. Emirik, F. Yılmaz et al. · Bioorganic chemistry (Print) · 2 citations